Bristol Myers Squibb Raises 2026 Revenue Forecast Following Strong Q2 Earnings

What's Happening? Bristol Myers Squibb has increased its full-year revenue forecast after reporting better-than-expected second-quarter earnings. The company's revenue for the quarter reached $12.97 billion, a 6% increase from the previous year, driven by strong sales of the blood thinner Eliquis an

Markets & Economy

SEE ALL

Trendline

Point72's Market Intelligence Team Expands with New Sector Analyst Role

Reuters

BOJ Governor Ueda's comments at news conference

Trendline

Increased Government Spending Boosts Profits for UK Defence Firms

What is the story about?

What's Happening?

Bristol Myers Squibb has increased its full-year revenue forecast after reporting better-than-expected second-quarter earnings. The company's revenue for the quarter reached $12.97 billion, a 6% increase from the previous year, driven by strong sales

of the blood thinner Eliquis and newer drugs like Camzyos and Reblozyl. Eliquis alone generated $4.48 billion, marking a 22% increase. The company now anticipates Eliquis sales to grow between 20% and 25% for the year, surpassing earlier projections. This performance has led to an upward revision of the company's financial outlook for 2026.

Why It's Important?

The revised revenue forecast underscores Bristol Myers Squibb's strong market position and the successful integration of new products into its portfolio. The robust sales of Eliquis and other drugs highlight the company's ability to capitalize on market opportunities and meet healthcare demands. This financial performance can boost investor confidence and support the company's strategic initiatives. Additionally, the success of Eliquis, shared with Pfizer, reflects the importance of strategic partnerships in the pharmaceutical industry.